Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus CLEMASTINE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus CLEMASTINE FUMARATE.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY vs CLEMASTINE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
1.34 mg orally twice daily; max 8.04 mg/day
None Documented
None Documented
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Category A/B
Category C
Antihistamine
Antihistamine